LGND
HealthcareLigand Pharmaceuticals Incorporated
$192.03
+$1.92 (+1.01%)
Jan 5, 2026
Price History (1Y)
Analysis
Ligand Pharmaceuticals Incorporated is a biotechnology company operating in the healthcare sector. With a market capitalization of $3.78 billion and revenue of $251.23 million (TTM), it has a significant presence within its industry. The company employs 68 individuals. From a financial perspective, Ligand Pharmaceuticals Incorporated exhibits notable profitability metrics. Its gross margin is 61.6%, operating margin is 46.9%, and profit margin is 19.3%. In terms of returns, the company achieves a return on equity (ROE) of 5.4% and a return on assets (ROA) of 1.5%. The balance sheet shows that Ligand Pharmaceuticals Incorporated has $664.52 million in cash, against debt of $451.00 million, resulting in a debt to equity ratio of 47.47. The valuation context for Ligand Pharmaceuticals Incorporated is characterized by a P/E ratio (TTM) of 84.97 and forward P/E of 22.82. The company's revenue growth has been substantial at 122.8% year-over-year, though earnings growth figures are not available. In terms of dividend information, the payout ratio is 0.0%, indicating that no dividends are currently paid out.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Visit website →Key Statistics
- Market Cap
- $3.78B
- P/E Ratio
- 84.97
- 52-Week High
- $212.49
- 52-Week Low
- $93.58
- Avg Volume
- 195.09K
- Beta
- 0.83
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 68